Position Statements, Practice Statements, and Practice Guidelines
The need for authoritative guidance in pediatric pharmacy practice has grown with changes in health care and with shifting influences from regulatory, accrediting, risk-management, financing, and other bodies. The PPA Advocacy Committee develops official professional position statements for this purpose.
PPA offers therapeutic position statements that respond to specific therapeutic issues. These statements are thorough, evidence-based recommendations of drug use. PPA also offers position statements on public policy issues that are directed to health care professionals, public officials, and the general public.
PPA position statements provide guidance and direction to PPA members, pharmacy practitioners, and other audiences who affect pharmacy practice. Their use by members and other practitioners is strictly voluntary, and their content should be assessed and adapted to meet the needs of specific practice settings.
Below is a list of our guidelines and position statements:
Endorsed the Institute of Safe Medication Practices (ISMP) Medication Safety Self Assessment for High-Alert Medications (2017)
Medication dosing in overweight and obese children (2017 update)
Duty to Advocate: Human Papillomavirus Vaccination (2017 update)
[[In the Press: Pharmacy Times]]
Pediatric Antimicrobial Stewardship Programs (2017 updated)
Heparin Safety Concerns (2016)
Recommendations for Meeting the Pediatric Patient's Need for a Clinical Pharmacist: A Joint Opinion of the Pediatrics Practice and Research Network of the American College of Clinical Pharmacy and the Pediatric Pharmacy Advocacy Group (2012)
Statement on self-administration of asthma medication for school-aged children (2003, legacy paper)
Guidelines for preventing medication errors in pediatric patients (2001, legacy paper)